Saturday 17 October 2026
Export SVRA’s income statement to Excel — free account
Savara Inc.
SVRA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 14.3%, free cash flow fell 14.1% and total debt rose 1.54%, each against the same quarter a year earlier.
4.45
0.29
−6.12%
Follow SVRA
Savara Inc. (SVRA) P/E ratio
Savara Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2020 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2020 | 0.0× | — |
| Sep 2020 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IMTX Immatics N.V. compare | n/m |
| JANX Janux Therapeutics, Inc. compare | n/m |
| ANRO Alto Neuroscience, Inc. compare | n/m |
| MNKD MannKind Corporation compare | n/m |
| CGEM Cullinan Therapeutics, Inc. compare | n/m |
| SVRA Savara Inc. | n/m |
| AKTS Aktis Oncology, Inc. compare | n/m |
| RIGL Rigel Pharmaceuticals, Inc. compare | 2.6× |
| MGTX MeiraGTx Holdings PLC compare | 12.2× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)